ATE361067T1 - Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen - Google Patents
Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungenInfo
- Publication number
- ATE361067T1 ATE361067T1 AT02745640T AT02745640T ATE361067T1 AT E361067 T1 ATE361067 T1 AT E361067T1 AT 02745640 T AT02745640 T AT 02745640T AT 02745640 T AT02745640 T AT 02745640T AT E361067 T1 ATE361067 T1 AT E361067T1
- Authority
- AT
- Austria
- Prior art keywords
- alzheimer
- treatment
- neurodegenerative diseases
- inhibitors
- tau aggregation
- Prior art date
Links
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 3
- 238000004220 aggregation Methods 0.000 title abstract 2
- 230000002776 aggregation Effects 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 abstract 2
- 230000004770 neurodegeneration Effects 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 241000276398 Opsanus tau Species 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 235000012711 vitamin K3 Nutrition 0.000 abstract 1
- 239000011652 vitamin K3 Substances 0.000 abstract 1
- 229940041603 vitamin k 3 Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0117326.9A GB0117326D0 (en) | 2001-07-16 | 2001-07-16 | Napthoquinone-type inhibitors of protein aggregation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE361067T1 true ATE361067T1 (de) | 2007-05-15 |
Family
ID=9918593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02745640T ATE361067T1 (de) | 2001-07-16 | 2002-07-16 | Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7605179B2 (de) |
| EP (1) | EP1408952B1 (de) |
| JP (1) | JP5147157B2 (de) |
| CN (1) | CN1313088C (de) |
| AT (1) | ATE361067T1 (de) |
| AU (1) | AU2002317354B2 (de) |
| CA (1) | CA2451422C (de) |
| DE (1) | DE60219917T2 (de) |
| ES (1) | ES2287292T3 (de) |
| GB (1) | GB0117326D0 (de) |
| SG (1) | SG148846A1 (de) |
| WO (1) | WO2003007933A1 (de) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| GB0100119D0 (en) | 2001-01-03 | 2001-02-14 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| GB0101049D0 (en) | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| GB0106953D0 (en) | 2001-03-20 | 2001-05-09 | Univ Aberdeen | Neufofibrillary labels |
| MXPA05013692A (es) * | 2003-06-23 | 2006-03-13 | Neurochem Int Ltd | Metodos para tratar trastornos por acumulacion de proteina. |
| WO2005053609A2 (en) * | 2003-11-26 | 2005-06-16 | Guilford Pharmaceuticals Inc. | Methods of nad+-dependent deacetylase inhibitors |
| WO2006007864A1 (en) * | 2004-07-17 | 2006-01-26 | Max Planck Geselllschaft Zur Förderung Der Wissenschaft | Treating neurodegenerative conditions |
| FR2874923B1 (fr) * | 2004-09-07 | 2006-10-27 | Trophos Sa | Application a titre de medicaments de derives du 3, 5-seco-4-nor-cholestane, compositions pharmaceutiques les renfermant, nouveaux derives et leur procede de preparation |
| JP5186212B2 (ja) | 2004-09-23 | 2013-04-17 | ウィスタ ラボラトリーズ リミテッド | メチルチオニニウム塩化物（ｍｔｃ）などのジアミノフェノチアジニウム化合物を化学合成および精製する方法 |
| JP4734602B2 (ja) | 2004-12-21 | 2011-07-27 | Ｄｏｗａエレクトロニクス株式会社 | 保存安定性に優れた窒化鉄系磁性粉末 |
| JP4822312B2 (ja) * | 2005-05-13 | 2011-11-24 | 学校法人慶應義塾 | ナフトキノン誘導体化合物 |
| KR100699945B1 (ko) * | 2005-11-24 | 2007-03-26 | (주) 디지탈바이오텍 | 나프토퀴논계 화합물을 함유하는 인지기능 장애의 예방 및 치료용 조성물 |
| CN104119294B (zh) | 2006-03-29 | 2018-10-30 | 维斯塔实验室有限公司 | 3,7-二氨基-10h-吩噻嗪化合物的制备方法 |
| DK2004155T3 (en) | 2006-03-29 | 2018-04-30 | Wista Lab Ltd | PROTEIN AGGREGATION INHIBITORS |
| WO2008002465A2 (en) * | 2006-06-23 | 2008-01-03 | The Feinstein Institute For Medical Research | INHIBITORS OF Aβ AND SYNUCLEIN AGGREGATION |
| EP2130533A4 (de) * | 2007-04-05 | 2010-04-21 | J Oil Mills Inc | Ataraktikum und funktionelles nahrungsmittel |
| JP2010538611A (ja) * | 2007-09-07 | 2010-12-16 | ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク | タウタンパク質スクリーニングアッセイ |
| EP2060256A1 (de) * | 2007-11-16 | 2009-05-20 | Gnosis S.p.A. | Auf Menaquinolen basierende pharmazeutische und nutrazeutische Zusammensetzungen |
| GB0816269D0 (en) * | 2008-09-05 | 2008-10-15 | Univ Ramot | Naphthoquinone derivatives useful for prevention of amyloid deposits and treatment of alzheimers disease |
| EP2550361B1 (de) | 2010-03-25 | 2017-02-08 | The J. David Gladstone Institutes | Zusammensetzungen und verfahren zur behandlung neurologischer störungen |
| US9320793B2 (en) * | 2010-07-14 | 2016-04-26 | Acumen Pharmaceuticals, Inc. | Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42 |
| US20130345312A1 (en) * | 2010-08-06 | 2013-12-26 | Orion D. Jankowski | Treatment of mitochondrial diseases with naphthoquinones |
| WO2012106363A2 (en) | 2011-01-31 | 2012-08-09 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| KR101888713B1 (ko) | 2011-02-11 | 2018-08-14 | 위스타 레보레이토리스 리미티드 | 페노티아진 디아미늄 염 및 이의 용도 |
| WO2012145169A2 (en) | 2011-04-21 | 2012-10-26 | The Regents Of The University Of California | Functionalized magnetic nanoparticles and use in imaging amyloid deposits and neurofibrillary tangles |
| WO2012170773A1 (en) * | 2011-06-08 | 2012-12-13 | Edison Pharmaceuticals, Inc. | Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones |
| US20140249180A1 (en) | 2011-10-03 | 2014-09-04 | National Center For Geriatrics And Gerontology | Tau aggregation inhibitor |
| US9938560B2 (en) | 2012-02-05 | 2018-04-10 | Biodesy, Inc. | Methods for identifying modulators of Ras using nonlinear techniques |
| EP2885010B1 (de) | 2012-08-16 | 2020-01-01 | Ipierian, Inc. | Verfahren zur behandlung einer tauopathie |
| CA2883879A1 (en) | 2012-09-07 | 2014-03-13 | Edison Pharmaceuticals, Inc. | Quinone derivatives for use in the modulation of redox status of individuals |
| WO2014066744A2 (en) | 2012-10-25 | 2014-05-01 | True North Therapeutics, Inc. | Anti-complement c1s antibodies and uses thereof |
| ES2912396T3 (es) | 2012-11-02 | 2022-05-25 | Bioverativ Usa Inc | Anticuerpos anti-C1s del complemento y uso de los mismos |
| EP2962687B1 (de) | 2013-04-02 | 2019-06-05 | The Doshisha | Tau-aggregationshemmer |
| SMT202000401T1 (it) | 2013-06-10 | 2020-11-10 | Ipierian Inc | Metodi di trattamento di una taupatia |
| CN105659087B (zh) * | 2013-06-13 | 2019-09-17 | 比奥德赛公司 | 筛选靶向靶生物实体的候选生物实体的方法 |
| US20150166476A1 (en) * | 2013-12-17 | 2015-06-18 | Yi-Cheng Chen | Methods for treating neurodegenerative diseases associated with aggregation of amyloid-beta |
| EP3237906B8 (de) | 2014-12-23 | 2020-10-28 | Bluelight Therapeutics, Inc. | Befestigung von proteinen an schnittstellen zur verwendung in nicht-linearer optischer detektion |
| US11628147B2 (en) | 2017-12-19 | 2023-04-18 | Synergia Life Sciences Pvt. Ltd. | Vitamin K2 compositions for the treatment of drug induced neuropathy |
| WO2019191773A1 (en) | 2018-03-30 | 2019-10-03 | Kaydence Pharma As | Rapidly improving vascular conditions by administering vitamin k |
| CN113874078B (zh) | 2019-04-05 | 2025-05-06 | Tauc3生物制品有限公司 | 抗tauc3抗体及其应用 |
| CN110025624B (zh) * | 2019-05-29 | 2021-04-02 | 济宁医学院附属医院 | 萘醌苷类化合物在老年痴呆中的应用及其药物制备 |
| CN112778092B (zh) * | 2020-12-31 | 2023-03-24 | 玉溪健坤生物药业有限公司 | 一种还原型维生素k2的制备方法及其用途 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59175449A (ja) * | 1983-03-26 | 1984-10-04 | Kyushu Kogyo Daigaku | シコニンの製造法 |
| JPS61143334A (ja) * | 1984-12-18 | 1986-07-01 | Mitsui Petrochem Ind Ltd | ５，８−ジヒドロキシ−１，４−ナフトキノン誘導体 |
| US4897388A (en) * | 1988-12-20 | 1990-01-30 | Geriatric Research Institute, Inc. | Method of treating Alzheimer's disease |
| DK0570414T3 (da) * | 1991-02-04 | 2000-11-06 | Ks Biomedix Ltd | Naphthoquinonderivater til behandling af kronisk inflammation |
| WO1993011231A1 (en) | 1991-12-06 | 1993-06-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Tools for the diagnosis and treatment of alzheimer's disease |
| WO1996004915A1 (en) | 1994-08-08 | 1996-02-22 | Albert Einstein College Of Medicine Of Yeshiva University | Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes |
| JPH08193026A (ja) * | 1995-01-12 | 1996-07-30 | Teijin Ltd | アミロイドβ蛋白凝集・沈着阻害剤 |
| DE19504003A1 (de) * | 1995-02-08 | 1996-08-14 | Martin Dr Kohlmeier | Verwendungen eines Vitamins der K-Gruppe |
| GB9506197D0 (en) * | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| US5804601A (en) | 1995-04-10 | 1998-09-08 | Takeda Chemical Industries, Ltd. | Aromatic hydroxamic acid compounds, their production and use |
| KR0180791B1 (ko) * | 1995-07-24 | 1999-05-15 | 김용옥 | 6-치환-5,8-디옥시-1,4-나프토퀴논 유도체, 그의 제조방법 및 그의 항암제로서의 용도 |
| JP3809014B2 (ja) * | 1998-05-22 | 2006-08-16 | 花王株式会社 | 養毛・育毛剤 |
| US20020040011A1 (en) | 2000-06-01 | 2002-04-04 | Brown Dennis M. | Naphthoquinone compositions and uses thereof |
| US20020016372A1 (en) | 2000-07-31 | 2002-02-07 | Allison Anthony Clifford | Method for preventing and treating alzheimer's disease and brain damage associated with cardiov ascular disease and head injury |
| GB0100119D0 (en) | 2001-01-03 | 2001-02-14 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| GB0101049D0 (en) | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| GB0106953D0 (en) | 2001-03-20 | 2001-05-09 | Univ Aberdeen | Neufofibrillary labels |
| US6953974B2 (en) * | 2003-08-26 | 2005-10-11 | Texas Instruments Incorporated | EEPROM device and method for providing lower programming voltage |
| GB0322756D0 (en) | 2003-09-29 | 2003-10-29 | Univ Aberdeen | Methods of chemical synthesis |
| WO2006032879A2 (en) | 2004-09-23 | 2006-03-30 | Wista Laboratories Ltd. | Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc) |
-
2001
- 2001-07-16 GB GBGB0117326.9A patent/GB0117326D0/en not_active Ceased
-
2002
- 2002-07-16 JP JP2003513541A patent/JP5147157B2/ja not_active Expired - Lifetime
- 2002-07-16 ES ES02745640T patent/ES2287292T3/es not_active Expired - Lifetime
- 2002-07-16 AT AT02745640T patent/ATE361067T1/de active
- 2002-07-16 AU AU2002317354A patent/AU2002317354B2/en not_active Expired
- 2002-07-16 SG SG200600959-1A patent/SG148846A1/en unknown
- 2002-07-16 EP EP02745640A patent/EP1408952B1/de not_active Expired - Lifetime
- 2002-07-16 US US10/483,266 patent/US7605179B2/en not_active Expired - Lifetime
- 2002-07-16 CA CA2451422A patent/CA2451422C/en not_active Expired - Lifetime
- 2002-07-16 CN CNB028177207A patent/CN1313088C/zh not_active Expired - Lifetime
- 2002-07-16 WO PCT/GB2002/003269 patent/WO2003007933A1/en not_active Ceased
- 2002-07-16 DE DE60219917T patent/DE60219917T2/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US20050107472A1 (en) | 2005-05-19 |
| EP1408952B1 (de) | 2007-05-02 |
| SG148846A1 (en) | 2009-01-29 |
| JP5147157B2 (ja) | 2013-02-20 |
| AU2002317354B2 (en) | 2007-07-19 |
| JP2004534854A (ja) | 2004-11-18 |
| ES2287292T3 (es) | 2007-12-16 |
| US7605179B2 (en) | 2009-10-20 |
| HK1063012A1 (en) | 2004-12-10 |
| CA2451422C (en) | 2010-10-19 |
| EP1408952A1 (de) | 2004-04-21 |
| WO2003007933A1 (en) | 2003-01-30 |
| DE60219917D1 (de) | 2007-06-14 |
| CN1553800A (zh) | 2004-12-08 |
| DE60219917T2 (de) | 2008-01-17 |
| CA2451422A1 (en) | 2003-01-30 |
| GB0117326D0 (en) | 2001-09-05 |
| CN1313088C (zh) | 2007-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60219917D1 (de) | Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen | |
| ATE409176T1 (de) | 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen | |
| EA200900802A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
| EA200600078A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
| DK1465626T3 (da) | Farmaceutiske præparater (kit) der omfatter dihydropyridinonforbindelser og et immunregulatorisk (eller et antiinflammatorisk) middel samt anvendelser deraf | |
| DE122012000007I1 (de) | Zusammenzetzungen und verfahren zur stabilisierungvon transthyretin und zur hemmung von transthyret infehlfaltung. | |
| ATE506951T1 (de) | Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit | |
| NO20071240L (no) | Terapeutiske anvendelser av RTP801 inhibitorer | |
| WO2005004803A3 (en) | Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease | |
| NO961326D0 (no) | Inhibitorer av | |
| ATE443043T1 (de) | Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer | |
| EA200501017A1 (ru) | Астма и модуляторы аллергических воспалений | |
| ATE517861T1 (de) | Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
| ATE480235T1 (de) | Verwendung von pramipexol zur behandlung von amyotrophischer lateralsklerose | |
| EA200600071A1 (ru) | Производные n-фенилпиперазина и способы профилактики или лечения заболеваний, связанных с 5ht-рецептором | |
| NO20063193L (no) | Fusjonerte pyrrolokarbazoler og fremgangsmater for fremstilling derav | |
| NO20044530L (no) | Fremgangsmate for behandling av kognitive forstyrrelser | |
| ATE432278T1 (de) | Verbindungen zur behandlung von krankheiten | |
| NO20015247L (no) | Glysinspaltingssysteminhibitorer som potensielle antipsykotika | |
| DE602004006118D1 (de) | 2,3,4,5-TETRAHYDROBENZOiFöi1,4öOXAZEPIN-5-CARBONSÄUREAMID DERIVATE ALS GAMMA-SECRETASE INHIBITOREN ZUR BEHANDLUNG VON ALZHEIMER | |
| ATE464048T1 (de) | Behandlung von alzheimer-krankheit und verwandten zuständen | |
| MXPA05013692A (es) | Metodos para tratar trastornos por acumulacion de proteina. | |
| ATE399758T1 (de) | Derivate von 1-phenylalkancarbonsäuren zur behandlung von neurodegenerativen krankheiten | |
| BR0314541A (pt) | Tratamento de demência e doença de parkinson | |
| DE602004024992D1 (de) | Verwendung von pyrazolopyridinen zur behandlung von kognitiven defiziten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1408952 Country of ref document: EP |